Good Health and Well- being in the Different Current Treatment Strategies for Coronavirus Disease 2019 (COVID-19): A mini Review

Abstract

People of all ages must lead healthy lives and advance wellbeing in order for sustainable development to occur. The global economy is being weakened by COVID-19, which is also disrupting the lives of billions of people worldwide. By the end of 2019, the novel coronavirus that causes severe acute respiratory syndrome (SARS-CoV2) abruptly began to spread, giving rise to the term coronavirus disease 2019 (COVID19). There is currently no proven treatment for COVID-19. Finding efficient therapies is urgently needed to care for patients and control the spread of SARS-CoV2 among humans. The treatment medicines that may be employed to fight the SARS-CoV2 infection were emphasized for the current review. Numerous medications have been repurposed for COVID19 therapy since the disease's emergence. Regarding the treatment of COVID-19, existing medications such as chloroquine (CQ), Along with chloroquine, We also investigated monoclonal antibodies, restorative plasma, Chinese herbal treatment, and natural compounds, including remdesivir, hydroxychloroquine (HCQ), and nucleoside analogues. Although initial clinical trials demonstrated that CQ/HCQ had antiviral activities, further investigations revealed significant debate over its suitability for treating COVID-19. Preventing the virus from interacting with human cell receptors for angiotensin converting enzyme 2 is one of these medicinal medicines' biological defenses against SARS-CoV2. Many of studies about the role of nanomaterials in treating Covid-19, based on their unique physical, chemical and biological properties, which depend on shape and size, as the use of nanomaterials is considered a promising future to eliminate viruses, including Covid-19.

Keywords:

COVID-19, antiviral treatment, vaccine treatment, plasma treatment

References

World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected.https://www.who.int/publicationsdetail/clinicalmanagement-of-severe-acute-respiratory infection-when-novel-coronavirus-(ncov)-infection-issuspected.

- Phadke, M. and Saunik, S. (2020). COVID‐19 treatment by repurposing drugs until the vaccine is in sight. Drug Development Research, PP: 1-3. https://doi.org/10.1002/ddr.21666,wileyonlinelibrary.com/journal/ddr.

- National Health Commission of the People’s Republic of China.(2020). Diagnosis and Treatment of Pneumonia Caused by 2019-nCoV (version 6). [Google Scholar]

- WHO.(2020). Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. https://www.who.int/publications-detail/clinical-management-of severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed 28 Jan 2020.

- Chen L, Xiong J, Bao L, Shi Y. (2020). Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020. 10.1016/s1473-3099(20)30141-9.

- Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. (2016). Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 15(5):327–347. doi: 10.1038/nrd.2015.37.

- Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al.(2020). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020. 10.1001/jama. 1585 [Epub ahead of print].

- Li H, Wang YM, Xu JY, Cao B. (2020). Potential antiviral therapeutics for 2019 Novel Coronavirus. Chin J Tuberc Respir Dis. 43(0):E002.

- Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al.(2018). Coronavirus susceptibility to the antiviral remdesivir (gs-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 9(2):e00221–e00218. doi: 10.1128/mBio.00221-18.

- Holshue Michelle L., DeBolt Chas, Lindquist Scott, Lofy Kathy H., Wiesman John, Bruce Hollianne, Spitters Christopher, Ericson Keith, Wilkerson Sara, Tural Ahmet, Diaz George, Cohn Amanda, Fox LeAnne, Patel Anita, Gerber Susan I., Kim Lindsay, Tong Suxiang, Lu Xiaoyan, Lindstrom Steve, Pallansch Mark A., Weldon William C., Biggs Holly M., Uyeki Timothy M., Pillai Satish K.(2020). First Case of 2019 Novel Coronavirus in the United States. New England Journal of Medicine. 382(10):929–936. doi: 10.1056/NEJMoa2001191.

- Aguiar ACC, Murce E, Cortopassi WA, Pimentel AS, Almeida M, Barros DCS, et al.(2018). Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity. Int J Parasitol Drugs Drug Resist. 8(3):459–464. doi: 10.1016/j.ijpddr.2018.10.002.

- Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. (2003). Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis. 3(11):722–727. doi: 10.1016/S1473-3099(03)00806-5.

- Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al.(2005). Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2:69. doi: 10.1186/1743-422X-2-69.

- Golden EB, Cho HY, Hofman FM, Louie SG, Schonthal AH, Chen TC. (2015). Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg Focus. 38(3):E12. doi: 10.3171/2014.12.FOCUS14748.

- Wang Manli, Cao Ruiyuan, Zhang Leike, Yang Xinglou, Liu Jia, Xu Mingyue, Shi Zhengli, Hu Zhihong, Zhong Wu, Xiao Gengfu.(2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. 30(3):269–271. doi: 10.1038/s41422-020-0282-0.

- Cvetkovic RS, Goa KL. (2003).Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 63(8):769–802. doi: 10.2165/00003495-200363080-00004.

- Arabi YM, Asiri AY, Assiri AM, Aziz Jokhdar HA, Alothman A, Balkhy HH, et al. (2020). Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials. 21(1):8. doi: 10.1186/s13063-019-3846-x.

- Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. (2004).Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 59(3):252–256. doi: 10.1136/thorax.2003.012658.

- Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. (2020). Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 35(6):e79. doi: 10.3346/jkms.2020.35.e79.

- Wang Z, Chen X, Lu Y, Chen F, Zhang W.(2020). Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 10.5582/bst.2020.01030.

- Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. (2003).Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis. 3(11):722–727. doi: 10.1016/S1473-3099(03)00806-5.

- Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al.(2005). Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2:69. doi: 10.1186/1743-422X-2-69.

- Golden EB, Cho HY, Hofman FM, Louie SG, Schonthal AH, Chen TC. (2015). Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg Focus. 38(3):E12. doi: 10.3171/2014.12.FOCUS14748.

- Wang Manli, Cao Ruiyuan, Zhang Leike, Yang Xinglou, Liu Jia, Xu Mingyue, Shi Zhengli, Hu Zhihong, Zhong Wu, Xiao Gengfu. (2020).Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. 30(3):269–271. doi: 10.1038/s41422-020-0282-0.

- Cvetkovic RS, Goa KL.(2003). Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 63(8):769–802. doi: 10.2165/00003495-200363080-00004.

- Arabi YM, Asiri AY, Assiri AM, Aziz Jokhdar HA, Alothman A, Balkhy HH, et al.(2020). Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials. 21(1):8. doi: 10.1186/s13063-019-3846-x.

- Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. (2004).Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 59(3):252–256. doi: 10.1136/thorax.2003.012658.

- PAAASLD-IDSA H Guidance & Panel Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018;67(10):1477–1492. doi: 10.1093/cid/ciy585.

- Tsang K, Zhong NS. (2003). SARS: pharmacotherapy. Respirology. 2003;8(Suppl 1):S25–S30. doi: 10.1046/j.1440-1843.2003.00525.x.

- Arabi YM, Shalhoub S, Mandourah Y, Al-Hameed F, Al-Omari A, Al Qasim E, et al. (2019). Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: a multicenter observational study. Clin Infect Dis. 10.1093/cid/ciz544 .

- McQuade B, Blair M.(2015). Influenza treatment with oseltamivir outside of labeled recommendations. Am J Health. 72(2):112–116.

- Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ.(2014). Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 348:g2545. doi: 10.1136/bmj.g2545.

- Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al.(2018). Coronavirus susceptibility to the antiviral remdesivir (gs-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 9(2):e00221–e00218. doi: 10.1128/mBio.00221-18.

- Tchesnokov EP, Feng JY, Porter DP, Gotte M.(2019). Mechanism of inhibition of ebola virus rna-dependent rna polymerase by remdesivir. Viruses. 11(4):E326. doi: 10.3390/v11040326.

- Lo MK, Feldmann F, Gary JM, Jordan R, Bannister R, Cronin J, et al.(2019). Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci Transl Med. 11(494):eaau9242. doi: 10.1126/scitranslmed.aau9242.

- Hsieh HP, Hsu JT. (2007). Strategies of development of antiviral agents directed against influenza virus replication. Curr Pharm Des. 13(34): 3531–3542. doi: 10.2174/138161207782794248.

- Nishimura H, Yamaya M. A.(2015). synthetic serine protease inhibitor, Nafamostat Mesilate, is a drug potentially applicable to the treatment of ebola virus disease. Tohoku J Exp Med. 237(1):45–50. doi: 10.1620/tjem.237.45.

- Al-Badr AA, Ajarim TDS. (2018). Ganciclovir. Profiles Drug Subst Excip Relat Methodol. 43:1–208. doi: 10.1016/bs.podrm.2017.12.001.

- Shiraki K. (2018). Antiviral drugs against alphaherpesvirus. Adv Exp Med Biol. 1045:103–122. doi: 10.1007/978-981-10-7230-7_6.

- Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. (2013). Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir Res. 100(2):446–454. doi: 10.1016/j.antiviral.2013.09.015.

- Goldhill DH, Te Velthuis AJW, Fletcher RA, Langat P, Zambon M, Lackenby A, et al. (2018). The mechanism of resistance to favipiravir in influenza. P Natl Acad Sci USA. 115(45):11613–11618. doi: 10.1073/pnas.1811345115.

- Cardile AP, Warren TK, Martins KA, Reisler RB, Bavari S. (2017). Will there be a cure for Ebola? Annu Rev Pharmacol. 57:329–348. doi: 10.1146/annurev-pharmtox-010716-105055.

- Rossignol JF.(2014). Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antivir Res. 110:94–103. doi: 10.1016/j.antiviral.2014.07.014.

- Cao J, Forrest JC, Zhang X.(2015). A screen of the NIH clinical collection small molecule library identifies potential anti-coronavirus drugs. Antivir Res. 114:1–10. doi: 10.1016/j.antiviral.2014.11.010.

- Rossignol JF. (2016). Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health. 9 (3):227–230. doi: 10.1016/j.jiph.2016.04.001.

- Fedson, D. (2016). Treating the host response to emerging virus disease. Annals of Translational Medicine, 4(21), 421.

- Hoffmann, M., Kleine‐Weber, H., Schroeder, S.,Krüger, N., Herrler, T., Erichsen, S., … Pöhlmann, S. (2020). SARS‐CoV‐2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically‐Proven Protease Inhibitor. Cell. https://doi.org/10.1016/j-cell2020.02.052.

- ProgenaBiome.(2020). A study of hydroxychloroquine, vitamin C, vitamin D, and zinc for the prevention of COVID-19 infection (HELPCOVID-19). Retrieved April 9, 2020. Available on the World Wide Web at: https://clinicaltrials.gov/ct2/show/NCT04335084?cond=COVID&intr=zinc&draw=2&rank=2

- Istinye University.(2020). Proflaxis using hydroxychloroquine plus vitamins-zinc during COVID-19 pandemia. Retrieved April 9, 2020. Available on the World Wide Web at:

https://clinicaltrials.gov/ct2/show/NCT04326725?cond=COVID&intr=zinc&draw=2&rank=3

- Progena Bione.(2020). A study of quintuple therapy to treat COVID-19 infection (HAZCpaC). Retrieved April 9, 2020. Available on the World Wide Web at:

https://clinicaltrials.gov/ct2/show/NCT04334512?cond=COVID&intr=zinc&draw=2&rank=4

- University of Melbourne.(2020). World-first trial to test benefit of intravenous zinc in COVID-19 fight. Retrieved April 9, 2020. Available on the World Wide Web at:

https://medicalxpress.com/news/2020-04-world-first-trial-benefit-intravenous-zinc.html

- University of Palermo.(2020). Use of ascorbic acid in patients With COVID 19. Retrieved April 9, 2020. Available on the World Wide Web at:

https://clinicaltrials.gov/ct2/show/NCT04323514?cond=COVID&intr=vitamin+C&draw=2&rank =1

- Providence Health and Services.(2020). Hydroxychloroquine in patients with newly diagnosed COVID-compared to standard of care. Retrieved April 9, 2020. Available on the World Wide Web at:

https://clinicaltrials.gov/ct2/show/NCT04334967?cond=COVID&intr=vitamin+C&draw=2&rank= 4

- Washington University.(2020). Hydroxychloroquine for COVID-19 PEP. Retrieved April 9, 2020.Available on the World Wide Web at:

https://clinicaltrials.gov/ct2/show/NCT04328961?cond=COVID&intr=vitamin+C&draw=2&rank= 5

- ZhiYong Peng. (2020).Vitamin C infusion for the treatment of severe 2019-nCoV infected pneumonia. Retrieved April 9, 2020. Available on the World Wide Web at:

https://clinicaltrials.gov/ct2/show/NCT04264533?cond=COVID&intr=vitamin+C&draw=2&rank= 6

- Universite de Sherbrooke.(2020). Lessening organ dysfunction with vitamin C (LOVIT). Retrieved April 9,2020. Available on the World Wide Web at:

https://clinicaltrials.gov/ct2/show/NCT03680274?cond=COVID&intr=vitamin+C&draw=2&rank= 8

- Universidad de Granada.(2020). Vitamin D on Prevention and Treatment of COVID-19 (COVITD-19).Retrieved April 9, 2020. Available on the World Wide Web at:

https://clinicaltrials.gov/ct2/show/NCT04334005?cond=COVID&intr=Vitamin+D&draw=2&rank= 1

- National Institutes of Health (NIH). (2020). Zinc: fact sheet for health professionals. Retrieved April 9, 2020. Available on the World Wide Web at: https://ods.od.nih.gov/factsheets/ZincHealthProfessional/

- National Institutes of Health (NIH).(2020). Vitamin C: fact sheet for health professionals. Retrieved April 9, 2020.Available on the World Wide Web at: https://ods.od.nih.gov/factsheets/VitaminCHealthProfessional/

- National Institutes of Health (NIH).(2020). Vitamin D: fact sheet for health professionals. Retrieved April 9, 2020.Available on the World Wide Web at: https://ods.od.nih.gov/factsheets/VitaminDHealthProfessional/

- Song, Z., Xu, Y., Bao, L., Zhang, L., Yu, P., Qu, Y., … Qin, C. (2019). From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses, 11(1), 59.

- Luo H, Tang Q-L, Shang Y-X, Liang S-B, Yang M, Robinson N, et al.(2020). Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin J Integr Med. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32065348.

- WHO. (2020). Pocket book of hospital care for children: guidelines for the management of common childhood illnesses. Geneva: World Health Organization; 2013

http://www.who.int/maternal_child_adolescent/documents/child_hospital_care/en/, accessed 4 March 2020.

- Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E et al.(2012). Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526-33. Epub 2012/07/17. Doi:10.1001/jama.2012.5669.

- Khemani RG, Smith LS, Zimmerman JJ, Erickson S,(2015). Pediatric Acute Lung Injury Consensus Conference G Pediatric acute respiratory distress syndrome: definition, incidence, and epidemiology: proceedings from the Pediatric Acute Lung Injury Consensus Conference. Pediatr Crit Care Med. 2015;16(5 Suppl 1):S23-40. Epub 2015/06/04. Doi 10.1097:

- Riviello ED, Kiviri W, Twagirumugabe T, Mueller A, Banner-Goodspeed VM, Officer L et al.(2016). Hospital incidence and outcomes of the acute respiratory distress syndrome using the Kigali modification of the Berlin Definition. Am J Respir Crit Care Med. 2016;193(1):52-9. Epub 2015/09/10. doi: 10.1164/rccm.201503-0584OC.

- Goldstein B, Giroir B, Randolph A, (2005).International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005;6(1): 2-8. Epub 2005/01/08. doi: 10.1097/01.PCC.0000149131.72248.E6.

- Davis AL, Carcillo JA, Aneja RK, Deymann AJ, Lin JC et al. (2017).American College of Critical Care Medicine clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. Crit Care Med 2017;45(6):1061-93.

Epub 2017/05/17. doi: 10.1097/CCM.0000000000002425.

- Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H et al.(1996). The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707-10. Epub 1996/07/01. doi: 10.1007/bf01709751

- Park WB, Poon LLM, Choi SJ, Choe PG, Song KH, Bang JH et al. (2018).Replicative virus shedding in the respiratory tract of patients with Middle East respiratory syndrome coronavirus infection. Int J Infect Dis. 2018;72:8-10. Epub 2018/05/13. doi: 10.1016/j.ijid.2018.05.003.

- Yan G, Lee CK, Lam LTM, Yan B, Chua YX, Lim AYN et al. (2020).Covert COVID-19 and false-positive dengue serology in Singapore. Lancet Infect Dis. 2020. Epub 2020/03/08. doi: 10.1016/S1473-3099(20)30158-4.

- WHO. (2020). Oxygen therapy for children: a manual for health workers. Geneva: World Health Organization; 2013

http://www.who.int/maternal_child_adolescent/documents/child-oxygen-therapy/en/, accessed 10 March 2020.

- Choi, J.Y.(2020). Convalescent Plasma Therapy for Coronavirus Disease 2019.Infect Chemother. 2020 Sep;52(3):307-316 https://doi.org/10.3947/ic.2020.52.3.307. PP: 307- 316.

- Casadevall A, Pirofski LA. (2020).The convalescent sera option for containing COVID-19. J Clin Invest 2020;130(4):1545–8.

- Luke TC, Kilbane EM, Jackson JL, Hoffman SL.(2006). Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006;145(8):599–609.

- Soo YO, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KK, et al. (2004).Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004;10(7):676–8.

- Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al.(2011). Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1).2019 virus infection. Clin Infect Dis 2011;52(4):447–56.

- Zhou B, Zhong N, Guan Y. (2007).Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007;357(14):1450–1.

- Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during out breaks. Geneva: World Health Organization; 2014. Available: www.who.int/csr/resource s/publications/ebola/convalescent-treatment/en (Accessed 16 July 2020).

- Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. (2020).Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020;117(17):6-9490.

- Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al.(2020). Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020;323(16):1582–9.

- Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, et al.(2020). Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol 2020;92(10):901-1890.

- Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, et al. (2020). Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 2 infection. Chest 2020;158(1):e9–13.

- Salazar E, Perez KK, Ashraf M, Chen J, Castillo B, Christensen PA, et al.(2020). Treatment of COVID-19 patients with convalescent plasma in Houston, Texas. medRxiv; 2020.

- FDA. Investigational covid-19 convalescent plasma-emergency INDs. https://www. fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device- exemption ideprocess-cber/investigational-covid-19-convalescent-plasma-emergency-inds.

- Seghatchian J, Lanza F. Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: a rousing message of clinical benefit to both donors and recipients alike. Transfus Apher Sci 2020;59. June (3):102794.

- Lanza F, Seghatchian J.(2020). Reflection on passive immunotherapy in those who need most: some novel strategic arguments for obtaining safer therapeutic plasma or autologous antibodies from recovered COVID-19 infected patients. Br J Haematol. 2020;190(July (1)):e27–9.

- Casadevall A, Pirofski LA.(2020). The convalescent sera option for containing COVID-19. J Clin Invest 2020;130(April (4)):1545–8.nfection. Chest 2020;158(1):e9–13.

- Nguyen, T., Bang, D. D., and Wolff, A. (2019). Novel coronavirus disease (COVID- 19): Paving the road for rapid detection and point-of-care diagnostics. Micromachines 11, 1–7. doi:10.3390/MI110303062020

- Chan, W. C. W. (2020). Nano Research for COVID-19. ACS Nano 14 (4), 3719–3720. doi:10.1021/acsnano.0c02540

- Chauhan, G., Madou, M. J., Kalra, S., Chopra, V., Ghosh, D., and Martinez-Chapa, S. O. (2020). Nanotechnology for COVID-19: Therapeutics and Vaccine Research. ACS Nano 14 (7), 7760–7782. doi:10.1021/acsnano.0c04006

- Sharma, A., Kontodimas, K., and Bosmann, M. (2021). Nanomedicine: A Diagnostic and Therapeutic Approach to COVID-19. Front. Med., 8. doi:10.3389/fmed.2021.648005

- Cheng, L.-C., Jiang, X., Wang, J., Chen, C., and Liu, R.-S. (2013). Nano–bio effects: interaction of nanomaterials with cells. Nanoscale 5, 3547–3569. doi:10.1039/ C3NR34276J

- Zhu, M., Nie, G., Meng, H., Xia, T., Nel, A., and Zhao, Y. (2013). Physicochemical Properties Determine Nanomaterial Cellular Uptake, Transport, and Fate. Acc. Chem. Res. 46, 622–631. doi:10.1021/ar300031y

- Liu, Y., Workalemahu, B., and Jiang, X. (2017). The Effects of Physicochemical Properties of Nanomaterials on Their Cellular Uptake In Vitro and In Vivo. Small 13, 1701815. doi:10.1002/smll.201701815

- Abd Ellah, N. H., Gad, S. F., Muhammad, K., E Batiha, G., and Hetta, H. F. (2020). Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19. Nanomedicine 15, 2085–2102. doi:10.2217/ nnm-2020-0247

- Barar, J. (2020). COVID-19 clinical implications: the significance of nanomedicine. BioImpacts BI 10, 137. doi:10.34172/bi.2020.16

- Bonam, S. R., Kotla, N. G., Bohara, R. A., Rochev, Y., Webster, T. J., and Bayry, J. (2020). Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections. Nano Today, 101051. doi:10.1016/j.nantod.2020.101051

- Shapiro, R. S. (2021). COVID-19 vaccines and nanomedicine. Int. J. Dermatol. doi:10.1111/ijd.15673

- Varahachalam, S. P., Lahooti, B., Chamaneh, M., Bagchi, S., Chhibber, T., Morris, K., et al. (2021). Nanomedicine for the SARS-CoV-2: state-of-the-art and future prospects. Int. J. Nanomedicine 16, 539. doi:10.2147/ijn.s283686

- Itani, R., Tobaiqy, M., and Al Faraj, A. (2020). Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients. Theranostics 10, 5932–5942. doi:10.7150/thno.46691

- Łoczechin, A., Séron, K., Barras, A., Giovanelli, E., Belouzard, S., Chen, Y. T., et al. (2019). Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus. ACS Appl. Mater. Inter. 11, 42964–42974. doi:10.1021/acsami.9b15032

- Sarkar, S. (2020). Silver nanoparticles with bronchodilators through nebulisation to treat COVID 19 patients. Curr. Med. Res. 3, 449–450. doi:10.15520/ jcmro.v3i04.276

- Zachar, O. (2020). Formulations for COVID-19 Early Stage Treatment via Silver Nanoparticles Inhalation Delivery at Home and Hospital. Sci. Prepr.

- Doremalen, V. (2020). c or r e sp ondence Aerosol and Surface Stability of SARS- CoV-2 as Compared with SARS-CoV-1. Nejm, 0–2.

- Orecchioni, M., Bedognetti, D., Newman, L., Fuoco, C., Spada, F., Hendrickx, W., et al. (2017). Single-cell mass cytometry and transcriptome profiling reveal the impact of graphene on human immune cells. Nat. Commun., 1109. doi:10.1038/ s41467-017-01015-3

- Kostarelos, K. (2020). Nanoscale nights of COVID-19. Nat. Nanotechnol. 15, 343–344. doi:10.1038/s41565-020-0687-4

- Garber, K. (2018). Alnylam launches era of RNAi drugs. Nat. Biotechnol. 36, 777–778. doi:10.1038/nbt0918-777

- Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., et al. (2020). An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. N. Engl. J. Med. 383 (20), 1920–1931. doi:10.1056/NEJMoa2022483

- McKay, P. F., Hu, K., Blakney, A. K., Samnuan, K., Brown, J. C., Penn, R., et al.(2020). Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat. Commun. 11, 3523. doi:10.1038/s41467-020-17409-9

- Al-Jandeel TJ, Al-Karawi AS, Abdulrazzaq OI, Tareq S. An Evaluation of Laboratory Tests for COVID-19 Infection in Patients Residing in the Baghdad-Iraq. International Journal of Chemical and Biochemical Sciences, 2023; 23(1).

- T.J. Al-Jindeel, A.S. Al-Karawi, H.O. Kready, M. Mohammed. (2021). Prevalence of COVID-19 virus infection in asymptomatic volunteers in Baghdad city/Iraq during 2021. International Journal of Health Sciences. 6(S2): 5524-5530.